Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Warren Olanow

Showing results (61-70 of 189) with videos related to

Pageof 19
Sort By:
JAMA|January 22, 2004
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptionsAnthony H V Schapira, C Warren Olanow
Movement Disorders : Official Journal of the Movement Disorder Society|September 11, 2008
Levodopa therapy for Parkinson's disease: challenges and future prospectsC Warren Olanow, Andrew Lees, Jose Obeso
Annals of Neurology|January 8, 2009
Drug selection and timing of initiation of treatment in early Parkinson's diseaseAnthony H V Schapira, C Warren Olanow
Annals of Neurology|April 1, 2003
Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's diseaseAnthony H V Schapira, C Warren Olanow
Neurobiology of Aging|October 7, 2005
Protein aggregation in the pathogenesis of familial and sporadic Parkinson's diseaseKevin St P McNaught, C Warren Olanow
Movement Disorders : Official Journal of the Movement Disorder Society|December 6, 2017
New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United StatesKarl Kieburtz, Russell Katz, C Warren Olanow
Annals of Neurology|September 17, 2013
Therapeutic prospects for Parkinson diseaseC Warren Olanow, Anthony H V Schapira
The Lancet. Neurology|July 22, 2006
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implicationsC Warren Olanow, Jose A Obeso, Fabrizio Stocchi
Neurologic Clinics|October 27, 2004
Neuroprotective agents in Parkinson's disease: clinical evidence and caveatsThomas D Hälbig, Winona Tse, C Warren Olanow
Neurology|May 28, 2009
The scientific and clinical basis for the treatment of Parkinson disease (2009)C Warren Olanow, Matthew B Stern, Kapil Sethi
Pageof 19

Showing results (61-70 of 189) with videos related to

Sort By:
Pageof 19
JAMA|January 22, 2004
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptionsAnthony H V Schapira, C Warren Olanow
Movement Disorders : Official Journal of the Movement Disorder Society|September 11, 2008
Levodopa therapy for Parkinson's disease: challenges and future prospectsC Warren Olanow, Andrew Lees, Jose Obeso
Annals of Neurology|January 8, 2009
Drug selection and timing of initiation of treatment in early Parkinson's diseaseAnthony H V Schapira, C Warren Olanow
Annals of Neurology|April 1, 2003
Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's diseaseAnthony H V Schapira, C Warren Olanow
Neurobiology of Aging|October 7, 2005
Protein aggregation in the pathogenesis of familial and sporadic Parkinson's diseaseKevin St P McNaught, C Warren Olanow
Movement Disorders : Official Journal of the Movement Disorder Society|December 6, 2017
New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United StatesKarl Kieburtz, Russell Katz, C Warren Olanow
Annals of Neurology|September 17, 2013
Therapeutic prospects for Parkinson diseaseC Warren Olanow, Anthony H V Schapira
The Lancet. Neurology|July 22, 2006
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implicationsC Warren Olanow, Jose A Obeso, Fabrizio Stocchi
Neurologic Clinics|October 27, 2004
Neuroprotective agents in Parkinson's disease: clinical evidence and caveatsThomas D Hälbig, Winona Tse, C Warren Olanow
Neurology|May 28, 2009
The scientific and clinical basis for the treatment of Parkinson disease (2009)C Warren Olanow, Matthew B Stern, Kapil Sethi
Pageof 19